Adaptive Biotechnologies (ADPT) Current Assets (2018 - 2026)

Adaptive Biotechnologies has disclosed Current Assets across 9 years of filings, most recently posting $420.6 million for Q2 2026.

• In Q2 2026, Current Assets rose 60.61% year-over-year to $420.6 million; the TTM figure through Jun 2026 stood at $420.6 million (up 60.61% YoY), while the FY2025 annual figure was $300.2 million, up 5.79% from the prior year.
• Current Assets came in at $420.6 million for Q2 2026 at Adaptive Biotechnologies, up from $291.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $564.4 million in Q3 2022 to a low of $256.5 million in Q1 2025.
• Average Current Assets over 5 years is $385.4 million, with a median of $392.1 million recorded in 2023.
• Year-over-year, Current Assets tumbled 45.21% in 2022 and surged 60.61% in 2026.
• Over 5 years, Current Assets stood at $562.1 million in 2022, then declined by 27.03% to $410.2 million in 2023, then plunged by 30.82% to $283.8 million in 2024, then climbed by 5.79% to $300.2 million in 2025, then jumped by 40.1% to $420.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $420.6 million in Q2 2026, $291.8 million in Q1 2026, and $300.2 million in Q4 2025.